First patients have been served, launching the Nurse
Practitioner Group partnership to expedite and expand access to the
Eversense® E3 CGM
GERMANTOWN, Md., Nov. 3, 2022
/PRNewswire/ -- Senseonics Holdings, Inc. (NYSE American: SENS), a
medical technology company focused on the development and
manufacturing of long-term, implantable continuous glucose
monitoring (CGM) systems for people with diabetes, and Ascensia
Diabetes Care, a global diabetes care company, maker of the
CONTOUR® blood glucose monitoring (BGM) system portfolio and
exclusive distributor of Eversense® CGM Systems, today
announced the launch of a collaboration with the Nurse Practitioner
Group (NPG), a leader in multidisciplinary health services and
medical staffing solutions. The first patient insertion of the up
to 6-month Eversense E3 sensor by NPG was recently completed in
Florida, with plans to expand this
new initiative to other key markets across the U.S. in the coming
months.
Led by Senseonics and utilizing NPG's broad network of healthcare
providers in over 30 states, this partnership is designed to
broaden access to the Eversense® E3 CGM System by providing
convenient at-home and in-office insertion options for diabetes
patients. Under the agreement between Senseonics and NPG, NPG
providers will be certified to perform Eversense procedures in the
specified geographies and will offer its services for patients who
have been prescribed Eversense. Senseonics will assist NPG as they
set up their Eversense procedure capabilities in select geographic
areas.
Nurse practitioner-owned-and-operated, NPG has a track record of
delivering outstanding health care services to patients in multiple
environments, including private sector, government-contracted and
social service agencies. Senseonics, Ascensia and NPG view this
collaboration as a scalable solution with the goal of expanding
access to the Eversense E3 CGM System, enhancing the patient
experience, and streamlining the Eversense workflow for health care
providers who elect not to do insertions themselves, thus
broadening the universe of clinicians who prescribe Eversense.
"This partnership will expand options for existing and new
Eversense users by making additional providers available for
at-home or in-office device insertions," said Tim Goodnow, PhD, President and Chief Executive
Officer of Senseonics. "As Ascensia continues to drive Eversense E3
uptake in the U.S., we are excited to partner with the innovative
team at NPG to make it more convenient to begin or continue
receiving the benefits of this next generation CGM."
"The Nurse Practitioner Group is dedicated to providing quality
healthcare to the diverse communities we serve through innovative,
cost-effective strategies and this partnership aligns with our
commitment of providing outstanding service and remarkable
results," said Stacey Santiago, MSN,
FNP-BC, President and Chief Executive Officer of the Nurse
Practitioner Group. "Dedicated members of our skilled staff will be
trained and certified on the Eversense® E3 CGM System insertion and
removal procedures and credentialed to bill regionally. We are
excited to offer Eversense users a convenient, professional
solution for their twice-a-year insertions."
"Expanding and expediting access to this long-term, fully
implantable CGM system is Ascensia's number one priority and so we
are thrilled to announce this inititaive," added Rob Schumm, President of Ascensia Diabetes Care.
"Not only will more and more people with diabetes have access
to Eversense CGM, but also the opportunity to have the insertion
and removal procedures done in their homes or a nearby clinic. This
added convenience is possible thanks to this collaboration with
NPG."
Logo -
https://mma.prnewswire.com/media/749389/Ascensia_Diabetes_Care_Logo.jpg